STudy of Real-world Individualized Precision-oncology

Summary

The goal of this clinical trial is to learn if drugs that are matched to tumor DNA mutations work to treat metastatic solid cancers in adults. The main questions it aims to answer are: Is tumor worsening delayed for a longer period of time if patients take drugs that match DNA mutations, compared to if they take standard of care drugs? Researchers will compare drugs matched to tumor DNA mutations to standard of care drugs to see if the matched drugs work better, and to see if tumor worsening can be delayed for longer the more DNA mutations the drugs target. Participants will: Take drugs matched to tumor DNA mutations or standard of care drugs based on the regular dosing schedule of the drugs. Visit the clinic every approximately 2 months for checkups and tumor imaging.

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Molecularly matched therapy

  Molecularly matched therapy, as identified by a molecular tumor board, to match molecular alterations/biomarkers found in the tumor or circulating tumor DNA.

• Drug
  Standard of care

  Standard of care therapy for the tumor type.

Location